

Global Blood Therapeutics, Inc.  
 Form 4  
 December 16, 2016

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Third Rock Ventures II, L.P.

2. Issuer Name and Ticker or Trading Symbol  
 Global Blood Therapeutics, Inc.  
 [GBT]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction  
 (Month/Day/Year)

\_\_\_\_ Director  
 \_\_\_\_ Officer (give title below)  
 10% Owner  
 \_\_\_\_ Other (specify below)

C/O THIRD ROCK VENTURES,  
 LLC, 29 NEWBURY STREET, 3RD  
 FLOOR

12/14/2016

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

BOSTON, MA 02116

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
|                                 |                                      |  | Code                           | V   | Amount  | (A) or (D)   | Price   |
| Common Stock                    | 12/14/2016                           |  | J <sup>(1)</sup>               |   | 2,000,000   | D  | Ⓛ   |
| Common Stock                    |                                      |  |                                |   | 7,475,191   | D  | Ⓜ <sup>(2)</sup>                                      |
| Common Stock                    |                                      |  |                                |   | 191,502   | D  | Ⓜ <sup>(3)</sup>                                      |
| Common Stock                    |                                      |  |                                |   | 191,499   | D  | Ⓜ <sup>(3)</sup>                                      |
| Common Stock                    |                                      |  |                                |   | 191,501   | D  | Ⓜ <sup>(3)</sup>                                      |
| Common Stock                    |                                      |  |                                |   |   | D  | Ⓜ <sup>(5)</sup>                                      |
| Common Stock                    |                                      |  |                                |   |   | D  | Ⓜ <sup>(6)</sup>                                      |

Edgar Filing: Global Blood Therapeutics, Inc. - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Owned Beneficially (Instr. 3, 4, and 5) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|--|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable   | Expiration Date   | Title                                      | Amount or Number of Shares   |

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |         |       |
|---|---------------|-----------|---------|-------|
|   | Director      | 10% Owner | Officer | Other |
| Third Rock Ventures II, L.P.<br>C/O THIRD ROCK VENTURES, LLC<br>29 NEWBURY STREET, 3RD FLOOR<br>BOSTON, MA 02116    |               | X         |         |       |
| STARR KEVIN P<br>C/O MYOKARDIA, INC.,<br>333 ALLERTON AVENUE<br>SOUTH SAN FRANCISCO, CA 94080                       |               | X         |         |       |
| Third Rock Ventures GP II, L.P.<br>C/O THIRD ROCK VENTURES, LLC<br>29 NEWBURY STREET, 3RD FLOOR<br>BOSTON, MA 02116 |               | X         |         |       |
| TRV GP II, LLC<br>C/O THIRD ROCK VENTURES, LLC<br>29 NEWBURY STREET, 3RD FLOOR<br>BOSTON, MA 02116                  |               | X         |         |       |
| LEVIN MARK J<br>C/O THIRD ROCK VENTURES, LLC<br>29 NEWBURY STREET, 3RD FLOOR  |               | X         |         |       |

BOSTON, MA 02116

TEPPER ROBERT I  
 C/O THIRD ROCK VENTURES, LLC  
 29 NEWBURY STREET, 3RD FLOOR  
 BOSTON, MA 02116

X

## Signatures

|  |            |
|--|------------|
| /s/ Kevin Gillis, Chief Financial Officer of TRV GP II, LLC, general partner of Third Rock Ventures GP II, L.P., general partner of Third Rock Ventures II, L.P. | 12/16/2016 |
| __Signature of Reporting Person  | Date       |
| /s/ Kevin Gillis, Chief Financial Officer of TRV GP II, LLC, general partner of Third Rock Ventures GP II, L.P.  | 12/16/2016 |
| __Signature of Reporting Person  | Date       |
| /s/ Kevin Gillis, Chief Financial Officer of TRV GP II, LLC  | 12/16/2016 |
| __Signature of Reporting Person  | Date       |
| /s/ Kevin Gillis by power of attorney for Mark Levin   | 12/16/2016 |
| __Signature of Reporting Person  | Date       |
| /s/ Kevin Gillis by power of attorney for Kevin Starr  | 12/16/2016 |
| __Signature of Reporting Person  | Date       |
| /s/ Kevin Gillis by power of attorney for Dr. Robert Tepper  | 12/16/2016 |
| __Signature of Reporting Person  | Date       |

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on December 14, 2016, for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each

(1) such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

These shares are directly held by TRV II. The general partner of TRV II is TRV GP II. The general partner of TRV GP II is TRV GP II LLC. The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper").

(2) Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

(3) Includes shares received by Levin, Starr and Tepper, as applicable, in the distribution-in-kind described in footnote (1) above.

(4) These shares are directly held by Levin.

(5) These shares are directly held by Starr.

(6) These shares are directly held by Tepper.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.